Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Sai Parenteral's IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2001 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 294.88 Cr
Profile
Price Range 372  to  392 per share
Profile
Min Investment ₹392
Profile
Lot Size 1
Profile
Face Value ₹5
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Our Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems that include dry powder injections, pre-filled syringes, ampoules, and vials.We manufacture and sell Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. We started our export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. We export our products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors. Our Company’s CDMO business includes comprehensive solutions on product development, validation batches, stability studies, dossier compilation, international regulatory filings and commercial manufacturing. We believe that our R&D expertise and regulatory compliance capabilities positions us as a preferred CDMO partner for our customers in the Regulated and Semi-Regulated Markets. Our Company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte. Limited, has entered into a Share Purchase Agreement dated September 23, 2025 with Noumed Life Sciences Limited (UK), Mark Thulborne, and Jo-maree Delac to acquire a 74.60% majority and controlling stake in Noumed, including an equity infusion of AUD 4.00 million as a primary in Noumed Pharmaceuticals Pte Ltd, Australia. Noumed Pharmaceuticals Pty Limited (“Noumed”), an Australia-based pharmaceutical company in the business of Intellectual Property (IP) dossier-led commercialisation, integrated supply chain management with long-standing partnerships with retail pharmacy networks in Australia. For further details, please see “Objects of the Offer – Investment in wholly owned subsidiary, Sai Parenterals Pte Limited Read More

Basic Info

Face Value 5 per share

Price 372  to  392 per share

P/E (x) 72.6

Sales( Cr.) 163

PAT( Cr.) 14

EPS 5.4

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Anil Kumar Karusala Vijitha Gorrepati Karusala Aruna

Pre Issue Share Holding 61.23%

Post Issue Share Holding 51.1553%

Listing Details:

Listing Price: 405

Listing Gain: 3.21%

Current Price: 485.9

Gain On Issue: 485.9 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Mar 24, 2026
Closing Date Mar 27, 2026
Allotment Mar 30, 2026
Refund Mar 31, 2026
Delivery of Shares Mar 31, 2026
Listing Date Apr 01, 2026

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 38 14,896
Retail (Max) 13 494 193,648
S-HNI (Min) 14 532 208,544
S-HNI (Max) 67 2546 998,032
B-HNI (Min) 68 2584 1,012,928

Objective of the Issue

1. Capacity expansion and upgradation of manufacturing facilities 2. Establishment of a new R&D Centre 3. Repayment / prepayment of certain outstanding borrowings 4. Working capital requirements 5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) 6. General corporate purposes

Issue

Category Nos Bid Bid (x)
QIB 2112900 3610266 1.7x
NII 1622876 3831502 2.4x
Retail 3786710 439204 0.1x
EMP 0 0 0x
Total 7522486 7880972 1x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Sai Parenteral's Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 97 154 163
Other Income 0 2 1
Total Income 97 155 164
Total Expenditure 78 122 124
Operating Profit 19 33 40
Interest 6 11 12
Depreciation 6 9 8
Exceptional Income / Expenses 0 0 0
Profit Before Tax 7 13 20
Provision for Tax 3 4 5
Profit After Tax 4 8 14
Adjustments 0 0 -0
Profit After Adjustments 4 9 14
Adjusted Earnings Per Share 3.1 3.4 5.3

Sai Parenteral's Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 31 75 94
Minority's Interest 0 2 2
Borrowings 26 39 14
Other Non-Current Liabilities 0 -0 -0
Total Current Liabilities 77 153 162
Total Liabilities 134 267 272
Fixed Assets 44 70 53
Other Non-Current Assets 8 10 19
Total Current Assets 82 187 200
Total Assets 134 267 272

Sai Parenteral's Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 10 2 4
Cash Flow from Operating Activities -13 -30 33
Cash Flow from Investing Activities -19 -46 0
Cash Flow from Financing Activities 24 79 -36
Net Cash Inflow / Outflow -8 2 -2
Closing Cash & Cash Equivalent 2 4 2

Sai Parenteral's Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 3.06 3.35 5.33
CEPS(Rs) 7.11 6.73 8.5
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 22.02 28.13 35.19
Core EBITDA Margin(%) 19.15 20.54 24.15
EBIT Margin(%) 13.4 15.4 19.51
Pre Tax Margin(%) 7.49 8.17 12.21
PAT Margin (%) 4.52 5.47 8.85
Cash Profit Margin (%) 10.51 11.6 13.88
ROA(%) 3.27 4.19 5.35
ROE(%) 13.9 15.87 17.15
ROCE(%) 12.97 16.14 16.71
Receivable days 230.8 223.46 283.79
Inventory Days 49.73 59.82 98.79
Payable days 140.32 144.13 215.25
PER(x) 0 0 0
Price/Book(x) 0 0 0
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 0.78 0.83 0.64
EV/Core EBITDA(x) 4.02 3.86 2.63
Net Sales Growth(%) 0 58.85 6.08
EBIT Growth(%) 0 82.49 34.38
PAT Growth(%) 0 92.3 71.44
EPS Growth(%) 0 9.6 59.09
Debt/Equity(x) 2.18 1.59 1
Current Ratio(x) 1.07 1.23 1.23
Quick Ratio(x) 0.9 0.98 0.92
Interest Cover(x) 2.27 2.13 2.67
Total Debt/Mcap(x) 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 6% 0% 0% 0%
Operating Profit CAGR 21% 0% 0% 0%
PAT CAGR 75% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 17% 16% 16% 16%
ROCE Average 17% 15% 15% 15%

Company Contact Information

Sai Parenteral's Ltd.

Shivali Aggarwal

91 79979 91301

cs@saiparenterals.com

Plot No.39, 5th Floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K. V Seri Lingampally

IPO Lead Manager(s)

Sai Parenteral's Ltd.

Arihant Capital Markets Ltd.

Registrar Info

Sai Parenteral's Ltd.

Bigshare Services Pvt Ltd

G 10 Left Wing Amruta Village , Opp: Yashoda Hospital,Raj Bhavan Road,Somajiguda,Hyderabad

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!